Conquering Acute Respiratory Distress Syndrome ARDS and Cancer - Faron Pharmaceuticals

Endothelial barrier is everything

We all face life threatening conditions, if we lose the key property of vasculature - the endothelial barrier. Faron has identified several molecular mechanisms involved in the control of endothelial functions, providing opportunities to develop new unique drugs for true unmet medical need.

Read on ›
Drug development to save lives

Faron's lead drug platform Traumakine prevents vascular leakage through the injured endothelium of several central organs, potentially saving lives of seriously ill patients, e.g. those having acute respiratory distress syndrome (ARDS). The Clevegen project aims at recovering tumour immunity to help the host fight tumour growth and spread by controlling one of the key regulatory pathways connected to several cancers.

Read on ›
World-class expert network

Faron sources innovations from Academia and has built a strong expert network to execute drug development programs. The key opinion leaders play a crucial role in every step of our work, from inventions to clinical protocols and dissemination of results.

Read on ›
Many value inflection points in near future

Faron wants to create shareholder value, not only by advancing the pipeline but also by optimizing commercial steps of Faron products in various territories. Faron has already limited territorial licenses but retains all rights in Europe and USA for all proprietary drug candidates under development.

Read on ›

Lean Drug Development Company

Faron is a drug discovery and development company focussed on creating novel treatments for medical conditions with significant unmet needs. The company is based in Turku, Finland. Faron currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage.


TRAUMAKINE Phase III study targeting the treatment of ARDS

Faron has entered into pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). This study, called INTEREST, aims to achieve conditional European approval and has received €6 million European Union Framework Programme funding (FP7). Currently there is no available drug treatment for ARDS, an orphan lung disease which has a high 30–45% mortality rate.


Annual Results for the year ended 31 December 2015

10 March 2016 Faron announces its Annual Results. The Annual Report and accounts are available here.



Recent news

Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN) announced today that it has strengthened its Executive Management Team with the appointment of MD, PhD, eMBA Matti Karvonen as its new Medical Director. Dr. Karvonen will be responsible for overseeing Faron´s drug development strategy and will play a central role in expanding the clinical programmes of Traumakine® and Clevegen®.
Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN) announces today that it has filed two new patent applications on Clevegen®, its novel cancer immunotherapy drug candidate. The patents, which have been filed in Finland, are expected to be expanded to most countries over the next few years under the Patent Co-operation Treaty (PCT) and open up new opportunities for wider application of Clevegen® in conditions where removal of suppression of the local or systemic immunity is desired.
One of the Faron Founders and sources of innovation, Academician of Science Sirpa Jalkanen has been rewarded the second prize in the EU Women Innovators 2016 contest. A total of nine finalists competed for the EU Prize for Women Innovators 2016. The finalists were selected by a high-level jury consisting of independent experts from business, venture capital, entrepreneurship and academia. The first prize of 100,000 euros went to Dr Susana Sargento from Portugal.


Traumakine video

Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial.